214 reports of this reaction
1.5% of all TENOFOVIR DISOPROXIL FUMARATE TABLETS reports
#15 most reported adverse reaction
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME is the #15 most commonly reported adverse reaction for TENOFOVIR DISOPROXIL FUMARATE TABLETS, manufactured by Chartwell RX, LLC.. There are 214 FDA adverse event reports linking TENOFOVIR DISOPROXIL FUMARATE TABLETS to IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. This represents approximately 1.5% of all 14,129 adverse event reports for this drug.
Patients taking TENOFOVIR DISOPROXIL FUMARATE TABLETS who experience immune reconstitution inflammatory syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME is a less commonly reported adverse event for TENOFOVIR DISOPROXIL FUMARATE TABLETS, but still significant enough to appear in the safety profile.
In addition to immune reconstitution inflammatory syndrome, the following adverse reactions have been reported for TENOFOVIR DISOPROXIL FUMARATE TABLETS:
The following drugs have also been linked to immune reconstitution inflammatory syndrome in FDA adverse event reports:
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME has been reported as an adverse event in 214 FDA reports for TENOFOVIR DISOPROXIL FUMARATE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME accounts for approximately 1.5% of all adverse event reports for TENOFOVIR DISOPROXIL FUMARATE TABLETS, making it a notable side effect.
If you experience immune reconstitution inflammatory syndrome while taking TENOFOVIR DISOPROXIL FUMARATE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.